Among the proposed tools, advancements have been made with the implementation of Prostate-Specific Membrane Antigen (PSMA)–Positron Emission Tomography (PET)-based imaging and targeting; however, mpMRI remains the cornerstone for the diagnosis of PCa [14,15]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.